Wells Fargo & Company Vertex Pharmaceuticals Inc Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Wells Fargo & Company holds 830,220 shares of VRTX stock, worth $386 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

830,220

Previous 818,364 1.45%

Holding current value

$386 Million

Previous $384 Million 0.66%

% of portfolio

0.09%

Previous 0.09%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$460.0 - $505.78 $5.45 Million - $6 Million	11,856 Added 1.45%	830,220 $386 Million
Q2 2024 Aug 13, 2024	BUY	$392.81 - $485.53 $20 Million - $24.7 Million	50,797 Added 6.62%	818,364 $384 Million
Q1 2024 May 10, 2024	BUY	$407.69 - $446.08 $7.58 Million - $8.3 Million	18,601 Added 2.48%	767,567 $321 Million
Q4 2023 Feb 09, 2024	SELL	$343.0 - $410.68 $10.7 Million - $12.9 Million	-31,321 Reduced 4.01%	748,966 $305 Million
Q3 2023 Nov 13, 2023	SELL	$338.18 - $362.46 $9.24 Million - $9.91 Million	-27,328 Reduced 3.38%	780,287 $271 Million
Q2 2023 Aug 15, 2023	BUY	$314.42 - $351.91 $8.02 Million - $8.98 Million	25,507 Added 3.26%	807,615 $284 Million
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $9.4 Million - $10.7 Million	33,181 Added 4.43%	782,108 $246 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $8.39 Million - $9.43 Million	-29,344 Reduced 3.77%	748,927 $216 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $5.87 Million - $6.55 Million	-21,431 Reduced 2.68%	778,271 $225 Million
Q2 2022 Aug 12, 2022	SELL	$234.96 - $292.55 $12.1 Million - $15 Million	-51,380 Reduced 6.04%	799,702 $225 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $1.17 Million - $1.38 Million	5,278 Added 0.62%	851,082 $222 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $50.6 Million - $63.9 Million	-285,787 Reduced 25.26%	845,804 $186 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $7.58 Million - $8.48 Million	-41,789 Reduced 3.56%	1,131,591 $205 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $10.6 Million - $12.5 Million	-56,679 Reduced 4.61%	1,173,380 $237 Million
Q1 2021 May 13, 2021	SELL	$207.02 - $241.31 $15.5 Million - $18.1 Million	-75,085 Reduced 5.75%	1,230,059 $264 Million
Q4 2020 Feb 09, 2021	SELL	$207.01 - $276.09 $35.2 Million - $47 Million	-170,206 Reduced 11.54%	1,305,144 $308 Million
Q3 2020 Nov 05, 2020	SELL	$255.65 - $303.1 $13.2 Million - $15.7 Million	-51,698 Reduced 3.39%	1,475,350 $401 Million
Q2 2020 Aug 13, 2020	BUY	$225.48 - $295.8 $42.2 Million - $55.4 Million	187,264 Added 13.98%	1,527,048 $443 Million
Q1 2020 May 14, 2020	BUY	$199.77 - $247.81 $268 Million - $332 Million	1,339,784 New	1,339,784 $319 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Vertex Pharmaceuticals Inc Transaction History